ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1226

Neutrophil Activation Identifies Patients with Active Polyarticular Gout – a Role for Neutrophil Biomarkers in Monitoring Gout Disease Activity and Severity

Daisy Vedder 1, Martijn Gerritsen 1, Mike Nurmohamed 2, Ronald van Vollenhoven 3 and Christian Lood4, 1Amsterdam Rheumatology & immunology Center / Reade, Amsterdam, Netherlands, 2Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands, 3Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, 4University of Washington, Seattle, WA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biomarkers, gout, Neutrophil Extracellular Traps, neutrophils and Disease Activity

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Neutrophils are key immune cells participating in host defense through several mechanisms, including the formation of neutrophil extracellular traps (NETs). Excessive neutrophil activation has been linked to inflammation and autoimmunity, including gout. In gout models, uric acid crystals induce NETosis. NETs are known to induce inflammation and partake in induction of tissue damage. The role of NETs, however, in human gout has not been extensively investigated.

Our objective is to investigate the clinical utility of neutrophil-derived biomarkers in gout. We hypothesize that uric acid crystals activate neutrophils to form NETs contributing to immune cell activation, with subsequent arthritis and joint damage.

Methods: Plasma samples from 75 gout patients participating in the ‘Reade gout cohort Amsterdam’ were compared with 30 healthy controls (HC). Levels of NETs, and NET-derived markers (cell-free DNA and peroxidase activity) were analyzed using a MPO-DNA ELISA, as well as fluorimetry. Levels of calprotectin were analyzed by ELISA. Mitochondrial as well as genomic DNA levels were analyzed by qPCR. All markers were compared with HC and related to markers of inflammation and disease activity.

Results: Levels of NETs, as well as other neutrophil biomarkers, were increased in gout patients as compared to HC (p< 0.01, Figures 1A-B). No associations were found between markers of cell death (cfDNA and NETs) and disease activity. Genomic DNA, but not mitochondrial DNA, was elevated among gout patients (p< 0.05), and related to number of gout attacks (r=0.44, p=0.002). Peroxidase activity correlated with disease activity (RAPID score: r=0.43, p=0.01, RAPID function: r=0.54, p=0.001) and inflammation markers (CRP: r=0.40, p< 0.001, and ESR: r=0.43, p< 0.001). Involvement of ankle and wrist resulted in significant higher peroxidase levels compared to mono-articular disease (p=0.01, and p=0.03, respectively), indicating peroxidase activity being a marker of polyarticular gout (Figure 1C). Calprotectin (S100A8/A9) correlated with the inflammation markers CRP and ESR (r=0.30, p=0.01, and r=0.30, p=0.001, respectively) and morning stiffness, especially in patients with chronic polyarticular gout (r=0.61, p=0.001).

Conclusion: To our knowledge, this is the first report demonstrating presence of NETs in the peripheral blood of gout patients. Although markedly elevated, levels of NETs did not associate with markers of disease activity or inflammation, possibly due to the lack of inflammatory mitochondrial DNA within the NETs. Even so, our data demonstrate an important role of neutrophils in gout pathogenesis, with neutrophil activation markers associating with characteristics of active, and more pronounced polyarticular disease.


Disclosure: D. Vedder, None; M. Gerritsen, None; M. Nurmohamed, AbbVie, 2, 8, BMS, 2, 8, Celgene, 2, 8, Eli Lilly, 2, 8, Janssen, 2, 8, Merck, 2, 8, Pfizer, 2, 8, Roche, 2, 8, UCB, 2, 8; R. van Vollenhoven, AbbVie, 2, 9, Arthrogen, 2, AstraZeneca, 9, Biotest, 9, BMS, 2, 9, Celgene, 9, GSK, 2, 9, Janssen, 9, Lilly, 2, 9, medac, 9, Merck, 9, Novartis, 9, Pfizer, 2, 9, Roche, 9, UCB, 2, 9; C. Lood, None.

To cite this abstract in AMA style:

Vedder D, Gerritsen M, Nurmohamed M, van Vollenhoven R, Lood C. Neutrophil Activation Identifies Patients with Active Polyarticular Gout – a Role for Neutrophil Biomarkers in Monitoring Gout Disease Activity and Severity [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/neutrophil-activation-identifies-patients-with-active-polyarticular-gout-a-role-for-neutrophil-biomarkers-in-monitoring-gout-disease-activity-and-severity/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/neutrophil-activation-identifies-patients-with-active-polyarticular-gout-a-role-for-neutrophil-biomarkers-in-monitoring-gout-disease-activity-and-severity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology